Pliant Therapeutics (PLRX) News Today $14.37 +0.65 (+4.74%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Pliant Therapeutics (NASDAQ:PLRX) Trading 3.6% Higher - Time to Buy?Pliant Therapeutics (NASDAQ:PLRX) Trading 3.6% Higher - Here's WhyDecember 17 at 1:27 PM | marketbeat.comPliant Therapeutics Inc Ordinary SharesDecember 12, 2024 | morningstar.comPolar Asset Management Partners Inc. Acquires 123,600 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)Polar Asset Management Partners Inc. lifted its holdings in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 265.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 170,200 shares of the coDecember 6, 2024 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from AnalystsPliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) has been given a consensus recommendation of "Buy" by the nine research firms that are presently covering the firm, MarketBeat reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy ratingNovember 28, 2024 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Buy" from BrokeragesShares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) have been assigned an average recommendation of "Buy" from the nine ratings firms that are presently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy rating and one hasNovember 28, 2024 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) is Great Point Partners LLC's 3rd Largest PositionGreat Point Partners LLC reduced its stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 27.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,910,121 shares of the company's stockNovember 27, 2024 | marketbeat.comPositive Developments in Pliant Therapeutics’ IPF Research Bolster Buy RatingNovember 19, 2024 | markets.businessinsider.comPliant Therapeutics Reports Increased Losses and Strategic FocusNovember 19, 2024 | markets.businessinsider.comPliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024November 18, 2024 | globenewswire.comPromising Pipeline and Strong Financials Reinforce Buy Rating for Pliant TherapeuticsNovember 12, 2024 | markets.businessinsider.comBuy Rating on Pliant Therapeutics Driven by Promising Bexotegrast Developments and Strategic Market PositioningNovember 11, 2024 | markets.businessinsider.comOppenheimer Sticks to Their Buy Rating for Pliant Therapeutics (PLRX)November 9, 2024 | markets.businessinsider.comPositive Outlook on Pliant Therapeutics: Strategic Developments and Financial Stability Support Buy RatingNovember 9, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for Pliant Therapeutics (NASDAQ:PLRX)HC Wainwright restated a "buy" rating and set a $38.00 target price on shares of Pliant Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comPliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comHarbor Capital Advisors Inc. Boosts Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)Harbor Capital Advisors Inc. boosted its stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 233.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,979 shares of the companyNovember 7, 2024 | marketbeat.comPliant Therapeutics to Participate in the Stifel Healthcare ConferenceNovember 6, 2024 | markets.businessinsider.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Buy" by AnalystsPliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) has earned an average recommendation of "Buy" from the nine brokerages that are presently covering the company, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation and one has assigned a strong buNovember 3, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Stock, Insider Trading ActivityOctober 27, 2024 | benzinga.comPliant Therapeutics (NASDAQ:PLRX) Stock Quotes, Forecast and News SummaryOctober 26, 2024 | benzinga.comPliant Therapeutics (NASDAQ:PLRX) Stock Price Down 5.4% - Time to Sell?Pliant Therapeutics (NASDAQ:PLRX) Shares Down 5.4% - Here's What HappenedOctober 21, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Stock Price Up 4.5% - What's Next?Pliant Therapeutics (NASDAQ:PLRX) Stock Price Up 4.5% - What's Next?October 9, 2024 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of "Buy" from AnalystsPliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) has earned an average recommendation of "Buy" from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the cOctober 9, 2024 | marketbeat.comSquarepoint Ops LLC Takes $865,000 Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)Squarepoint Ops LLC acquired a new stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 80,475 shares of the company's stock, valued at approximately $865,000. Squarepoint Ops LLOctober 7, 2024 | marketbeat.comAlgert Global LLC Buys 52,912 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)Algert Global LLC raised its stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 312.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 69,842 shares of the company's stock after buying an additional 52,912 shaOctober 6, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Hits New 1-Year Low at $10.24Pliant Therapeutics (NASDAQ:PLRX) Sets New 1-Year Low at $10.24October 2, 2024 | marketbeat.comPliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical AffairsOctober 1, 2024 | globenewswire.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Renaissance Technologies LLCRenaissance Technologies LLC increased its stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 233.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 253,369 shares oOctober 1, 2024 | marketbeat.comPliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 30, 2024 | globenewswire.comPliant Therapeutics updates bylaws, aligns with Delaware lawSeptember 29, 2024 | investing.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by First Light Asset Management LLCFirst Light Asset Management LLC lessened its holdings in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 3.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,401,213 shares of thSeptember 24, 2024 | marketbeat.comPLRX Oct 2024 22.500 callSeptember 19, 2024 | ca.finance.yahoo.comPliant Therapeutics (NASDAQ:PLRX) Stock Price Down 2.7%Pliant Therapeutics (NASDAQ:PLRX) Trading Down 2.7%September 18, 2024 | marketbeat.comPliant Therapeutics (PLRX) Gets a Buy from Piper SandlerSeptember 18, 2024 | markets.businessinsider.comPliant Therapeutics (NASDAQ:PLRX) Sees Large Volume IncreasePliant Therapeutics (NASDAQ:PLRX) Sees Unusually-High Trading VolumeSeptember 17, 2024 | marketbeat.comPLRX Oct 2024 22.500 putSeptember 17, 2024 | ca.finance.yahoo.comPliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $12.00Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $12.00September 16, 2024 | marketbeat.comBullish on Bexo: Pliant Therapeutics’ Promising IPF Treatment Backed by Strong Clinical EvidenceSeptember 16, 2024 | markets.businessinsider.comPliant Therapeutics (NASDAQ:PLRX) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $38.00 target price on shares of Pliant Therapeutics in a research note on Friday.September 13, 2024 | marketbeat.comRice Hall James & Associates LLC Takes $1.37 Million Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)Rice Hall James & Associates LLC acquired a new stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 127,634 shares of the company's stock, valued at approxiSeptember 12, 2024 | marketbeat.comLeerink Partners sets Outperform rating on Pliant Therapeutics sharesSeptember 11, 2024 | uk.investing.comPliant Therapeutics: Good Data, But Will Need WatchingSeptember 11, 2024 | seekingalpha.comPliant Therapeutics (NASDAQ:PLRX) Shares Down 4.2% Pliant Therapeutics (NASDAQ:PLRX) Trading Down 4.2%September 11, 2024 | marketbeat.comPliant Therapeutics, Inc. Forecasted to Earn Q3 2024 Earnings of ($1.00) Per Share (NASDAQ:PLRX)Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2024 earnings per share estimates for shares of Pliant Therapeutics in a research report issued to clients and investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid forSeptember 11, 2024 | marketbeat.comPliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024September 10, 2024 | finance.yahoo.comPliant Therapeutics (NASDAQ:PLRX) Upgraded by Leerink Partnrs to "Strong-Buy"Leerink Partnrs upgraded Pliant Therapeutics to a "strong-buy" rating in a research note on Monday.September 10, 2024 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Coverage Initiated at Leerink PartnersLeerink Partners started coverage on Pliant Therapeutics in a research note on Monday. They issued an "outperform" rating and a $33.00 price objective on the stock.September 9, 2024 | marketbeat.comCandriam S.C.A. Boosts Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)Candriam S.C.A. boosted its stake in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 52.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 833,216 shares of the company's stock after acquiring an additional 285,216 shareSeptember 9, 2024 | marketbeat.comOppenheimer Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)September 5, 2024 | markets.businessinsider.comPliant Therapeutics to Participate in Upcoming Investor EventsAugust 28, 2024 | globenewswire.com Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Is Starlink Set For The Largest IPO In History? (Ad)He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! Click here now for the urgent details. PLRX Media Mentions By Week PLRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PLRX News Sentiment▼0.000.72▲Average Medical News Sentiment PLRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PLRX Articles This Week▼23▲PLRX Articles Average Week Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EWTX News JANX News XENE News MRUS News ACAD News TWST News MOR News VCEL News SWTX News ZLAB News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PLRX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLRX Stock Alerts